Skip to main content
Clinical Trials/NCT03210779
NCT03210779CompletedNot Applicable

Effect of Probiotic Tablets and Topical Probiotic Oil (Lactobacillus. Reuteri) on Oral Wound Healing (Pilot Study)

University of Copenhagen0 sites10 target enrollmentStarted: December 5, 2016Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
10
Primary Endpoint
Percentage (%) of initial wound size area, measured in digital photographs

Study Overview

Brief Summary

This research will study the healing of standardized wounds created in the oral mucosa of volunteer participants during daily intake of tablets and topical application of oil containing the probiotic bacterium Lactobacillus reuteri. Our null hypothesis is that the consumption and topical application of probiotic supplements containing L. reuteri does not improve clinical healing of oral wounds in healthy participants when compared to controls.

Detailed Description

Intervention: after informed consent and baseline collection of clinical data (age,sex), the participants will be randomly assigned to one of the order of the treatments. As a run-in period, they will be given a supply of probiotic or placebo tablets enough for seven days. The participants are instructed to take two tablets daily (one in the morning and one in the evening, days 0-7) and are asked to refrain from any other foods or supplements containing probiotics. On day eight, the participant will attend to the clinics and a punch biopsy will be performed. Depending on the allocation group, probiotic or placebo oil will be supplied. The participant will be instructed to apply the oil locally on the wound with a plastic microbrush for 9 days every evening, and strongly reinforced to continue with the assigned tablets twice daily. The participant will attend the clinics on days two, five and eight post-wounding for follow-up photographies of wound healing. The first intervention period terminates with a wash-out period of four weeks, and then the second run-in an intervention period start following the same procedures.

The probiotic tablets and the probiotic oil (at the recommended dose) contain 2x10^8 CFU of Lactobacillus reuteri. Both the placebo tablets and oil are identical in size and composition but without the addition of the probiotic strains. The tablets and oil are packed in identical pots/bottles with color coding. The code will be kept from the investigators until the analysis are finished. Both the tablets and oil are provided by BIOGAIA AB.

Clinical procedures and sampling

All clinical procedures and sample collections will be conducted by a qualified and authorized dentist from the Institute of Odontology, Section for Cariology, Endodontics, Pediatric Dentistry and Clinical Genetics, Faculty of Health and Medical Sciences, University of Copenhagen. Collected samples (saliva, wound exudate and bacterial smear) will be stored in a freezer at -80 °C until all samples from all patients are gathered -for a maximum of six months. Running of all collected samples at the same time allows laboratory analyses to be carried out efficiently and avoids errors.

Punch biopsy: on day eight, a standardized circular wound of 3.5 mm diameter and approximately 1.5 mm deep will be created in the mucosa of the hard palate with aid of a biopsy punch. The biopsy is performed under aseptic conditions and local anesthesia using lidocaine 2% combined with epinephrine for local hemostasis. A scalpel is used to remove the surface epithelium and underlying superficial connective tissue, which will be discarded according to biosafety regulations from the Institute of Dentistry, University of Copenhagen. After wounding, the wound site will be photographed (blind-coded) with an intraoral camera, placing a standard-sized 6 mm diameter template around the wound as reference. The participant will attend to the dental clinics on days two, five and eight post-wounding to have a photograph of the wound taken by Ph.D student Gina Castiblanco. The wound-size on photographs will be measured by two raters and will be expressed as the ratio of the wound surface area relative to the standard label size with aid of software (Canvas 7, ACD Systems of America). The endpoint will be the percentage of initial wound size, measured at days two, five and eight post-wounding.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Supportive Care
Masking
Double (Participant, Care Provider)

Masking Description

Double Blind (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Healthy individuals (no chronic compromising illnesses)
  • •Healthy oral conditions
  • •Good level of oral hygiene

Exclusion Criteria

  • •Adults over 50 years old
  • •Previous allergic reaction to local anesthetics
  • •Compromised oral mucosa
  • •Systemic diseases
  • •Alcoholism
  • •Smoking habit
  • •Pregnancy
  • •Antibiotic therapy within the last two months
  • •Active infection that needs treatment with antibiotics
  • •Systemic medications (glucocorticoid steroids, non-steroidal anti-inflammatory drugs -NSAIDS, chemotherapy, anticoagulant therapy) Contraceptives allowed.
  • •Thrombocytopenia or any of various inherited coagulopathies.
  • •Patients undergoing radiotherapy
  • •Inability to provide informed consent by means of physical or mental handicap

Arms & Interventions

L.reuteri

Active Comparator

L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 16 days + L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA probiotic oil, topically, once daily for 8 days.

Intervention: L. reuteri DSM 17938/ATCC PTA (Dietary Supplement)

Placebo

Placebo Comparator

Placebo lozenges three times daily for 16 days and placebo oil once daily for 8 days

Intervention: Placebo (Dietary Supplement)

Outcomes

Primary Outcomes

Percentage (%) of initial wound size area, measured in digital photographs

Time Frame: 8 days

The reference value (100%) will be the area before intervention. The percentage is calculated with the second measure (photograph after the intervention)

Secondary Outcomes

  • Levels of TNF-α and Interleukin 1β in the wound exudate(8 days)
  • Numerical estimation of S. aureus and β-haemolitic streptococci (CFU/ml)(8 days)
  • Levels of salivary oxytocin and salivary IL-10, in pg/ml(8 days)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Svante Twetman

Professor

University of Copenhagen

Similar Trials